Masimo Corporation

Masimo Corporation is a medical technology company that designs, manufactures, and markets noninvasive patient monitoring technologies. Its core offerings include pulse oximetry sensors, bedside and portable monitors, and related software platforms that measure blood oxygen saturation, pulse rate, and other physiological parameters. The company also provides advanced parameters such as carboxyhemoglobin, methemoglobin, and respiratory rate through its rainbow technology. Masimo serves hospitals, clinics, and alternative care settings across the United States and internationally.

The company maintains a global presence, with its products used in thousands of healthcare facilities worldwide. While specific employee or revenue figures are not cited here, Masimo is recognized as a significant player in the patient monitoring market and reports its financial results as a publicly traded entity. Its headquarters are located in the United States of America, and it operates research and development, manufacturing, and commercial operations in multiple regions.

Masimo distinguishes itself through its proprietary signal extraction technology (SET), which enables accurate measurements even under challenging conditions such as low perfusion or motion. The company holds a substantial portfolio of patents related to noninvasive sensing and has received numerous FDA clearances for its monitoring devices. Its focus on continuous innovation aims to improve patient safety, reduce the need for invasive blood draws, and lower healthcare costs through early detection of physiological changes.

Structurally, Masimo Corporation is an independent, publicly traded company listed on the NASDAQ under the ticker symbol MASI. It does not report a parent organization and oversees various subsidiaries that support its technology development, manufacturing, and global distribution efforts. The recent cybersecurity incident in April 2025 affected its on-premise manufacturing network, prompting containment measures and an ongoing investigation, while its cloud-based hospital services remained operational.